

Pneumococcal Vaccine Market Report and Forecast 2025-2034

Market Report | 2025-07-28 | 350 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4949.00
- Five User License \$5949.00
- Corporate License \$6969.00

Report description:

The pneumococcal vaccine market size was valued at USD 8.61 Billion in 2024 , driven by the emphasis on preventing invasive pneumococcal disease like pneumonia and meningitis across the 7 major markets. The market is expected to grow at a CAGR of 4.90% during the forecast period of 2025-2034, with the values likely to rise from USD 13.89 Billion by 2034 .

Pneumococcal Vaccine: Introduction

Pneumococcal vaccine is used to prevent pneumococcal disease, which is caused by the *Streptococcus pneumoniae* bacteria. This bacterium colonises the human respiratory tract and can induce both invasive (such as pneumonia, meningitis, bacteraemia) and non-invasive diseases (such as acute otitis media and sinusitis). Invasive diseases can even to hospitalisation and morbidity in patients.

There are two common types of pneumococcal vaccines used, namely pneumococcal conjugate vaccines (PCVs, specifically PCV15 and PCV20) and pneumococcal polysaccharide vaccine (PPSV23). PCV13 or PCV15 is commonly recommended to children younger than 2 years of age.

Pneumococcal Vaccine Market Analysis

Pneumonia accounts for 14% of children's deaths aged 5 years or younger. To curb this burden of mortality rates, researchers have been working towards effective vaccine solutions for infants and children. In April 2023, Pfizer's 20-valent pneumococcal conjugate vaccine, PREVNAR 20, received FDA approval. This vaccine offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine. It is built on PREVAR 13 and contains seven additional serotypes, related to antibiotic resistance and increased diseases severity.

The pneumococcal vaccine market value is also expected to grow with continuous advancements in the existing vaccines. Pneumovax 23 by Merck helps against fighting 23 types of pneumococcal bacteria. In August 2023, Merck revealed that their

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

investigational 21-valent PCV called V116 showcased significant immune responses in Phase 3 trials. It was applied on both, previously vaccinated and vaccine-naive adults.

In April 2023, Vaxcyte reported that their 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, designed specifically for patients 65 years or older showed positive data from the phase 2 study.

The technology used to create vaccines is experiencing a transition especially during the COVID-19 era. Researchers have started using novel techniques like 'Multiple Antigen Presenting System', or MAPS to create vaccines. This also indicates that the pneumococcal vaccine market demand will grow with the arrival of improved vaccines for quality treatment in patients.

Pneumococcal Vaccine Market Segmentation

Global Pneumococcal Vaccine Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Vaccine Type

- Conjugate vaccine
- Polysaccharide vaccine

Market Breakup by Product Type

- Prevnar 13
- Synflorix
- neumovax23

Market Breakup by Distribution Channel

- Distribution partner companies
- Non-governmental Organizations
- Government Authorities

Market Breakup by Region

- United States
- EU-4 and the United Kingdom
 - ??- Germany
 - ??- France
 - ??- Italy
 - ??- Spain
 - ??- United Kingdom

- Japan

Pneumococcal Vaccine Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The United States, with a well-developed infrastructure and being home to prominent healthcare companies, has dominated the pneumococcal vaccine market share in the historic period. With awareness campaigns and initiatives set up government and healthcare institutions, the population has become more accepting towards vaccinations. This has led to better vaccination rates in the region. In addition, the COVID-19 outbreak has made human bodies more susceptible to respiratory diseases, therefore, the demand for pneumococcal vaccine has surged.

Europe is expected to lead the market with the growing research and developments in the healthcare system. In April 2023, Spain hosted the 2nd Global Forum on childhood pneumonia which focused on preventing the fatal disease by providing vaccinations and medications to middle and low-income countries.

The Asia Pacific region is projected to have the highest pneumococcal vaccine market growth with several government initiatives to make the population undertake vaccinations. One such initiative is the SAANS (Social Awareness and Action to Neutralise Pneumonia Successfully) campaign by the Indian government, which spreads information on pneumonia prevention. Moreover, the region is also developing a robust infrastructure that supports advanced medical research and development for improved patient outcomes.

Pneumococcal Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- GlaxoSmithKline, Plc.
- Sanofi
- Merck & Co.
- Panacea Biotech
- Pfizer Inc
- PnuVax Incorporated
- SK bioscience
- Walvax Biotechnology Co.
- Beijing Minhai Biotechnology Co.
- Serum Institute of India

Table of Contents:

1 Preface

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Pneumococcal Disease Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Pneumococcal Disease Epidemiology Analysis - 7MM
 - 5.1 7MM Epidemiology Scenario Overview (2018-2034)
 - 5.2 United States Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.3 EU-4 and United Kingdom Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.3.1 Germany Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.3.2 France Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.3.3 Italy Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.3.4 Spain Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.3.5 United Kingdom Pneumococcal Disease Epidemiology Forecast (2018-2034)
 - 5.4 Japan Pneumococcal Disease Epidemiology Forecast (2018-2034)
- 6 Pneumococcal Vaccine Market Overview - 7MM
 - 6.1 Pneumococcal Vaccine Market Historical Value (2018-2024)
 - 6.2 Pneumococcal Vaccine Market Forecast Value (2025-2034)
- 7 Pneumococcal Vaccine Market Landscape - 7MM
 - 7.1 Pneumococcal Vaccine: Developers Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Pneumococcal Vaccine Product Landscape
 - 7.2.1 Analysis by Vaccine Type
 - 7.2.2 Analysis by Product Type
- 8 Pneumococcal Vaccine Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Pneumococcal Vaccine Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.7 Value Chain Analysis
- 11 Pneumococcal Vaccine Market Segmentation - 7MM
 - 11.1 Pneumococcal Vaccine Market by Vaccine Type
 - 11.1.1 Market Overview
 - 11.1.2 Conjugate vaccine
 - 11.1.3 Polysaccharide vaccine
 - 11.2 Pneumococcal Vaccine Market by Product Type
 - 11.2.1 Market Overview
 - 11.2.2 Prevnar 13
 - 11.2.3 Synflorix
 - 11.2.4 neumovax23
 - 11.3 Pneumococcal Vaccine Market by Distribution Channel
 - 11.3.1 Market Overview
 - 11.3.2 Distribution partner companies
 - 11.3.3 Non-governmental Organizations
 - 11.3.4 Government Authorities
 - 11.4 Pneumococcal Vaccine Market by Region
 - 11.4.1 Market Overview
 - 11.4.2 United States
 - 11.4.3 EU-4 and the United Kingdom
 - 11.4.3.1 Germany
 - 11.4.3.2 France
 - 11.4.3.3 Italy
 - 11.4.3.4 Spain
 - 11.4.3.5 United Kingdom
 - 11.4.4 Japan
- 12 United States Pneumococcal Vaccine Market
 - 12.1 Pneumococcal Vaccine Market Historical Value (2018-2024)
 - 12.2 Pneumococcal Vaccine Market Forecast Value (2025-2034)
 - 12.3 Pneumococcal Vaccine Market by Vaccine Type
 - 12.4 Pneumococcal Vaccine Market by Product Type
- 13 EU-4 and United Kingdom Pneumococcal Vaccine Market
 - 13.1 Pneumococcal Vaccine Market Historical Value (2018-2024)
 - 13.2 Pneumococcal Vaccine Market Forecast Value (2025-2034)
 - 13.3 Germany Pneumococcal Vaccine Market Overview
 - 13.3.1 Pneumococcal Vaccine Market by Vaccine Type
 - 13.3.2 Pneumococcal Vaccine Market by Product Type
 - 13.4 France Pneumococcal Vaccine Market Overview
 - 13.4.1 Pneumococcal Vaccine Market by Vaccine Type
 - 13.4.2 Pneumococcal Vaccine Market by Product Type
 - 13.5 Italy Pneumococcal Vaccine Market Overview
 - 13.5.1 Pneumococcal Vaccine Market by Vaccine Type
 - 13.5.2 Pneumococcal Vaccine Market by Product Type
 - 13.6 Spain Pneumococcal Vaccine Market Overview
 - 13.6.1 Pneumococcal Vaccine Market by Vaccine Type
 - 13.6.2 Pneumococcal Vaccine Market by Product Type
 - 13.7 United Kingdom Pneumococcal Vaccine Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.7.1 Pneumococcal Vaccine Market by Vaccine Type
- 13.7.2 Pneumococcal Vaccine Market by Product Type
- 14 Japan Pneumococcal Vaccine Market
- 14.1 Pneumococcal Vaccine Market Historical Value (2018-2024)
- 14.2 Pneumococcal Vaccine Market Forecast Value (2025-2034)
- 14.3 Pneumococcal Vaccine Market by Vaccine Type
- 14.4 Pneumococcal Vaccine Market by Product Type
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.1 GlaxoSmithKline, Plc.
 - 21.1.1 Financial Analysis
 - 21.1.2 Product Portfolio
 - 21.1.3 Demographic Reach and Achievements
 - 21.1.4 Mergers and Acquisitions
 - 21.1.5 Certifications
- 21.2 Sanofi
 - 21.2.1 Financial Analysis
 - 21.2.2 Product Portfolio
 - 21.2.3 Demographic Reach and Achievements
 - 21.2.4 Mergers and Acquisitions
 - 21.2.5 Certifications
- 21.3 Merck & Co.
 - 21.3.1 Financial Analysis
 - 21.3.2 Product Portfolio
 - 21.3.3 Demographic Reach and Achievements
 - 21.3.4 Mergers and Acquisitions
 - 21.3.5 Certifications
- 21.4 Panacea Biotech
 - 21.4.1 Financial Analysis
 - 21.4.2 Product Portfolio
 - 21.4.3 Demographic Reach and Achievements
 - 21.4.4 Mergers and Acquisitions
 - 21.4.5 Certifications
- 21.5 Pfizer Inc
 - 21.5.1 Financial Analysis
 - 21.5.2 Product Portfolio
 - 21.5.3 Demographic Reach and Achievements
 - 21.5.4 Mergers and Acquisitions
 - 21.5.5 Certifications
- 21.6 PnuVax Incorporated
 - 21.6.1 Financial Analysis
 - 21.6.2 Product Portfolio
 - 21.6.3 Demographic Reach and Achievements
 - 21.6.4 Mergers and Acquisitions
 - 21.6.5 Certifications
- 21.7 SK bioscience
 - 21.7.1 Financial Analysis
 - 21.7.2 Product Portfolio
 - 21.7.3 Demographic Reach and Achievements
 - 21.7.4 Mergers and Acquisitions
 - 21.7.5 Certifications
- 21.8 Walvax Biotechnology Co.
 - 21.8.1 Financial Analysis
 - 21.8.2 Product Portfolio
 - 21.8.3 Demographic Reach and Achievements
 - 21.8.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.8.5 Certifications
- 21.9 Beijing Minhai Biotechnology Co.
 - 21.9.1 Financial Analysis
 - 21.9.2 Product Portfolio
 - 21.9.3 Demographic Reach and Achievements
 - 21.9.4 Mergers and Acquisitions
 - 21.9.5 Certifications
- 21.10 Serum Institute of India
 - 21.10.1 Financial Analysis
 - 21.10.2 Product Portfolio
 - 21.10.3 Demographic Reach and Achievements
 - 21.10.4 Mergers and Acquisitions
 - 21.10.5 Certifications
- 22 Pneumococcal Vaccine Market- Distribution Model (Additional Insight)
 - 22.1 Overview
 - 22.2 Potential Distributors
 - 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
 - 24.1 Very Small Companies
 - 24.2 Small Companies
 - 24.3 Mid-Sized Companies
 - 24.4 Large Companies
 - 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
 - 25.1 Government Funded
 - 25.2 Private Insurance
 - 25.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pneumococcal Vaccine Market Report and Forecast 2025-2034

Market Report | 2025-07-28 | 350 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4949.00
	Five User License	\$5949.00
	Corporate License	\$6969.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com